Durable Remission with Immunotherapy in a Patient with Sarcomatoid Renal Cell Carcinoma

Main Article Content

Anusim Nwabundo
Gbadebo Damilola
Afolayan-Oloye Olabisi
Jaiyesimi Ishmael

Keywords

case study, immunotherapy, renal cell carcinoma, sarcomatoid differentiation

Abstract

Sarcomatoid differentiation is a rare and aggressive histologic subtype with poor prognosis, seen in several malignancies. In sarcomatoid renal cell carcinoma (RCC), the degree of sarcomatoid differentiation and the stage at presentation determines the prognosis. Despite resection, chemotherapy and targeted therapy response is modest, with relapse usually occurring within a few months. We present a case of a gentleman with sarcomatoid RCC managed with pembrolizumab, who has had no evidence of recurrence for over 4 years since the last dose of immunotherapy. RCCs with sarcomatoid differentiation have a high presence of programmed cell death protein 1 and programmed cell death ligand 1 in T cells and tumor cells, respectively, making immunotherapy an attractive option in this setting. Clinical trials are ongoing to further define the benefit of immunotherapy in sarcomatoid RCC.

Abstract 293 | PDF Downloads 85 HTML Downloads 41 XML Downloads 57

References

1. Kunene V, Miscoria M, Pirrie S, Islam MR, Afshar M, Porfiri E. Sarcomatoid renal cell carcinoma: Clinical outcome and survival after treatment with sunitinib. Clin Genitourin Cancer. 2014;12(4):251–255. 10.1016/j.clgc.2013.12.001

2. Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, et al. Outcomes of patients with renal cell carcinoma and sarcomatoid dedifferentiation treated with nephrectomy and systemic therapies: Comparison between the cytokine and targeted therapy eras. J Urol. 2017;198(3):530–537. 10.1016/j.juro.2017.04.067

3. Shuch B, Bratslavsky G, Shih J, Vourganti S, Finley D, Castor B, et al. Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma. BJU In. 2012;109(11):1600–1606. 10.1111/j.1464-410X.2011.10785.x

4. Ged Y, Chen YB, Knezevic A, Casuscelli J, Redzematovic A, DiNatale RG, et al. Metastatic chromophobe renal cell carcinoma: Presence or absence of sarcomatoid differentiation determines clinical course and treatment outcomes. Clin Genitourin Cancer. 2019 Jun;17(3):e678–e688. 10.1016/j.clgc.2019.03.018

5. Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, et al. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol. 2012;29(2):761–767. 10.1007/s12032-011-9829-8

6. Voss MH, Bastos DA, Karlo CA, Ajeti A, Hakimi AA, Feldman DR, et al. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. Ann Oncol. 2014;25(3):663–668. 10.1093/annonc/mdt578

7. Maiti A, Nemati-Shafaee M, Msaouel P, Pagliaro LC, Jonasch E, Tannir NM, et al. Phase 2 trial of capecitabine, gemcitabine, and bevacizumab in sarcomatoid renal-cell carcinoma. 2017; Aug:S1558-7673(17)30238-0. 10.1016/j.clgc.2017.07.028

8. Joseph RW, Millis SZ, Carballido EM, Bryant D, Gatalica Z, Reddy S, et al. PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation. Cancer Immunol Res. 2015;3(12):1303–1307. 10.1158/2326-6066.CIR-15-0150

9. Kwak C, Park YH, Jeong CW, Jeong H, Lee SE, Moon KC, et al. Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma. J Surg Oncol. 2007;95(4):317–323. 10.1002/jso.20669

10. El Mouallem N, Smith SC, Paul AK. Complete response of a patient with metastatic sarcomatoid renal cell carcinoma to a programmed death-1 checkpoint inhibitor. J Oncol Pract. 2018;14(8):511–513. 10.1200/JOP.18.00213

11. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019 Mar; 380(12):1116–1127. 10.1056/NEJMoa1816714

12. Tannir NM, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, Flaifel A, et al. Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Clin Cancer Res. 2021 Jan;27(1):78–86. 10.1158/1078-0432.CCR-20-2063